Avid Bioservices Inc (CDMO)

[biopharm]

Ampersand Capital knows about stock transfer possibly but shouldn't ALL Avid Bioservices shareholders be urgently concerned that TriPharm CDMO is ramping up for subcutaneous clients ...and TriPharm has Mark Bamforth and Patrick D Walsh diverting new and overflow subcutaneous client work from Avid CDMO to TriPharm

So TriPharm getting fully funded as Rick Hancock says no plans for Ampersand to fund bigger expansions ....when TriPharm looks to be diverting profits to TriPharm

Ampersand Capital playing dumb as Mercks lacky ....hell, Mark Bamforth bio from TriPharm page DOES NOT even mention Avid Bioservices so why diversion of client contracts??

Avid CDMO best continue sending in those certified letters / complaints etc to SEC FBI DOJ FDA etc because shade $hit going on as PPS suppressed as PS flipping inside Ampersand Capital cells and can not be trusted it seems.


_____

TriPharm Services announces creation of pharmaceutical manufacturing center

Capabilities Address Shortage of Qualified Parenteral Manufacturing Options in the U.S.

MORRISVILLE, NC, October 16, 2019
TriPharm Services, a new contract development and manufacturing organization (CDMO), is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment. The center of excellence specializes in injectable pharmaceutical capabilities including flexible manufacturing solutions for liquid and lyophilized products.
The facility, located at 627 Davis Drive in Morrisville and totaling 32,000 square feet, will offer four isolator filling suites and the highest level of control available for Grade A processing of client biologic and small molecule products. Featuring state-of-the-art equipment, the facility has eight multi-purpose cleanrooms to support manufacturing operations, along with modern, specialized utility systems to scale to client requirements.

Cofounders Patrick Walsh and Eric Evans have a long track record of creating high-growth organizations in the pharma industry and are backed by healthcare private equity firm Ampersand Capital Partners.

"TriPharm brings a new option to clients seeking modern, well-equipped manufacturing with an experienced leadership team," said Walsh.

"We are committed to providing a unique, high-quality service to our clients, given the global need for reliable, flexible and scalable manufacturing of injectable pharmaceuticals."

The state-of-the-art equipment and facility are set to be fully operable in the second quarter of 2020.

ABOUT TRIPHARM:

TriPharm is a CDMO offering parenteral manufacturing options for pharma and biotechnology clients. The formula is simple: Common sense, a founders mentality, and high-quality standards are applied vigorously around a relentless focus on client deliverables. www.TriPharm.com

ABOUT AMPERSAND CAPITAL PARTNERS:
Founded in 1988, Ampersand Capital Partners is a middle-market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Avista Pharma, Brammer Bio, Confluent Medical, Genoptix, Talecris Biotherapeutics, and Viracor-IBT Laboratories.

https://www.tripharm.com/tripharm-services-announces-creation-of-pharmaceutical-manufacturing-center/

_________

Mark R. Bamforth

Mark Bamforth founded a new CDMO, Arranta Bio, in May 2019.
Previously, Mark founded Brammer Bio in 2015, a best-in-class viral vector contract development and manufacturing organization (CDMO) supporting cell and gene therapies. Brammers team grew from 110 in 2016 with the addition of 100 from the acquisition of two Biogen commercial facilities, to over 600 at the time of its acquisition by Thermo Fisher Scientific in April 2019.

In 2010, Mark founded a biologics CDMO, Gallus BioPharmaceuticals, and acquired a world-class facility and team of 160 from J&J with a commercial supply agreement. Gallus tripled through organic growth and merging with Laureate Biopharma. Gallus was sold to DPx Holdings B.V. in Sept. 2014.
Mark previously spent 22 years in the UK and USA running a global manufacturing operation and a pharmaceutical CMO business for Genzyme and served as a corporate officer for 9 years.

He began his career as a petroleum engineer exploring for North Sea oil with Britoil, then as a chemical engineer in the whiskey industry with Whitbread.

Mark serves on the boards of Avid Bioservices, MassBio, Wentworth Institute of Technology, and Entrepreneurial Scotland. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College.


https://www.tripharm.com/about-us/mark-r-bamforth/

_______


Patrick D. Walsh

Pat has over thirty-five years of experience in the healthcare industry with extensive experience directing pharmaceutical manufacturing operations on a global scale in parenteral, API, specialty pharmaceutical, formulation, manufacturing and analytical contract development organizations.

Most recently, he served as the CEO of Avista Pharma Solutions and drove the rapid growth of the business, resulting in a pre-emptive sale of the company to Cambrex Corp in January 2019 for $252 million. Before Avista, he was CEO of AAIPharma Services and led the successful growth strategy, culminating in the sale of the company for 4.6 times return on invested capital.

Pat serves as an independent director of Avid Bioservices, MedPharm, and ANI Pharma. Prior board of director roles includes serving as Chairman of Brammer Bio and numerous other pharma and biotechnology companies.


https://www.tripharm.com/about-us/patrick-d-walsh-2/

_______


Trevor L. Wahlbrink

Mr. Wahlbrink is a Partner at private equity firm Ampersand Capital, and a member of the Ampersand team since 2012. Prior to his time at Ampersand, he was an Associate at Morgan Keegan where he worked on a number of leveraged acquisitions and recapitalizations of middle market companies. Prior to Morgan Keegan, Trevor was at Covington Associates, a specialty investment bank, where he focused on healthcare M&A transactions. Trevors in board seats have included Avista Pharma Solutions, Confluent, Elite One and ETE Medical. Trevor holds a M.S. and B.S. in Accounting and Finance from Boston College and is a CFA charter holder.


https://www.tripharm.com/about-us/trevor-l-wahlbrink/

______


Herbert H. Hooper

Mr. Hooper is the Managing Partner at Ampersand Capital, where he has worked since 2002. He brings an extensive background working with healthcare entrepreneurs and high growth organizations and has served on the board of numerous healthcare companies. His current and past board seats include ACLARA, Brammer Bio, Avista Pharma Services, GENEWIZ, Genoptix and Viracor-IBT Laboratories. He also serves on the College of Chemistry Advisory Board for the University of California, Berkeley. Herb holds a B.S. in Chemical Engineering from North Carolina State and a Ph.D. in Chemical Engineering from the University of California, Berkeley.


https://www.tripharm.com/about-us/herbert-h-hooper/

________